Wegovy weight loss results: what one month of data actually tells us

What did @prego_and_phat actually say?

Almost nothing about Wegovy, medically speaking. The caption claims a drop from 112kg to 109kg over one month on Wegovy, but the transcript itself is a motivational pep talk: "Girl, get back on track, regain your focus, and give the rest of this year everything you have got." There is no dosing information, no side effect discussion, and no clinical context offered in the spoken content.

That gap between caption and content matters. The 266,000 people who watched this video got a before-and-after weight number and an emotional rallying cry. Whether that 3kg loss reflects the drug working, water weight, dietary changes, or measurement differences is left entirely unaddressed. The video implies Wegovy caused the result without ever actually saying so, which is a pattern worth paying attention to.

Does the science back this up?

A 3kg loss in one month on Wegovy is plausible, but it sits at the lower end of what trials have documented, and early-phase results are almost always the least impressive part of the journey.

The landmark STEP 1 trial (Wilding et al., 2021, New England Journal of Medicine) followed 1,961 adults on 2.4mg semaglutide weekly for 68 weeks. Average weight loss was 14.9% of body weight. For someone starting at 112kg, that would be roughly 16.7kg total, not 3kg. Month one results in that trial were modest because most participants are still titrating up through lower doses, typically starting at 0.25mg and stepping up every four weeks.

So the numbers here are not wrong, they just tell an incomplete story. Early Wegovy results often understate the drug's eventual effect, and framing a one-month snapshot as a transformation is potentially misleading to viewers who might expect faster or more dramatic changes.

What did they get wrong (or right)?

What they got right: a 3kg reduction in month one is consistent with what early-stage semaglutide use looks like in clinical data, particularly during the dose escalation phase. It is honest, as far as it goes.

What is missing is significant. There is no mention of side effects, which in the STEP trials affected a majority of participants. Nausea was reported by roughly 44% of semaglutide users versus 16% on placebo (Wilding et al., 2021). No disclosure of whether dietary or exercise changes accompanied the weight loss. No acknowledgment that results vary substantially based on starting dose, adherence, and individual metabolic response.

The motivational framing, "get back on track," also subtly suggests the drug requires personal discipline to work, which is partially true but risks reinforcing stigma that weight loss medications work only if you try hard enough. The pharmacology of GLP-1 receptor agonists works on appetite signaling regardless of willpower, which is actually central to why these drugs represent a shift in how obesity medicine thinks about treatment.

What should you actually know?

If you are considering Wegovy based on videos like this one, here is what the studies actually show. First, one month is not a useful window for evaluating semaglutide. The STEP 1 trial ran 68 weeks for good reason: meaningful, sustained weight loss takes time and a fully titrated dose.

Second, not everyone responds the same way. A 2022 analysis by Rubino et al. in JAMA found that weight loss outcomes varied considerably across subgroups, with factors like baseline BMI, age, and metabolic health all influencing results. A 3kg first-month result could be followed by accelerating loss or a plateau, and neither outcome makes the drug a success or failure at that stage.

Third, Wegovy is a prescription medication approved for adults with a BMI of 30 or above, or 27 with at least one weight-related condition. It is not a supplement. It requires medical supervision, regular follow-up, and an honest conversation about your health history before starting. A TikTok before-and-after is not a substitute for that conversation.